Pay in 4 interest-free payments of $5.53 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
Patients should view brain-health benefits as an area of ongoing investigation rather than an established treatment outcome
Cai Y, Yang X, Chen S, Tian K, Xu S, Deng R, et al
if you are weighing whether to come off medication, read what happens if you stop treatment altogether, which is a separate conversation from tuning your dose down
Effect of H 2 O 2 on MRAB Biofilm Viability Multi-drug resistant A
Georgia Giannakopoulou, research manager, Ipsos Neurology Monitors Drug: PIPE-307 Company: Contineum Therapeutics Indication: Multiple sclerosis (remyelination) Stage: Phase II Background: PIPE307 is an oral, first-in-class, selective M1 muscarinic receptor antagonist aimed at promoting remyelination in relapsingremitting multiple sclerosis (RRMS)
US$ 19.99
US$ 29.52
US$ 27.45
